The executive chief of the European Union has said that the EU will donate a further 200 million COVID-19 vaccine doses to poorer countries and close gaps in its own vaccination coverage, Reuters news agency reported on Wednesday.
Ursula von der Leyen was quoted as telling the European Parliament in a speech in that the EU's first pandemic priority was to speed up global vaccination, given less than 1% of doses globally administered had been in low-income countries.
She said that European Commission will donate 200 million COVID-19 vaccine doses to low-income countries by the middle of next year, on top of the 250 million doses already pledged.
The European Commission president also said she saw "worrisome divergences" between the rates of vaccination in EU member states, adding that the bloc had secured 1.8 billion further vaccine doses to cover more initial and booster shots.
Von der Leyen added that the EU was setting up a health emergency response authority, designed to improve the bloc's response to cross-border health threats.
She also proposed that the EU invest EUR50bn by 2027 to improve its preparedness and resilience to future health threats.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML